Gestalt Diagnostics
Total Raised
$12.63MInvestors Count
6Funding, Valuation & Revenue
5 Fundings
Gestalt Diagnostics has raised $12.63M over 5 rounds.
Gestalt Diagnostics's latest funding round was a Series A for $7.5M on April 28, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
4/28/2025 | Series A | $7.5M | Cowles Company, Inland Imaging, Kickstart Fund, Tacoma Venture Fund, and Undisclosed Angel Investors | 3 | ||
4/15/2021 | Seed VC | |||||
4/11/2020 | Loan | |||||
1/17/2019 | Unattributed - II | |||||
3/10/2017 | Unattributed |
Date | 4/28/2025 | 4/15/2021 | 4/11/2020 | 1/17/2019 | 3/10/2017 |
|---|---|---|---|---|---|
Round | Series A | Seed VC | Loan | Unattributed - II | Unattributed |
Amount | $7.5M | ||||
Investors | Cowles Company, Inland Imaging, Kickstart Fund, Tacoma Venture Fund, and Undisclosed Angel Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 3 |
Gestalt Diagnostics Investors
6 Investors
Gestalt Diagnostics has 6 investors. Tacoma Venture Fund invested in Gestalt Diagnostics's Series A funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/15/2021 | 4/28/2025 | 2 Seed VC, Series A (2025) | Venture Capital | Washington | ||
Corporation | Washington | |||||
Venture Capital | Utah | |||||
Venture Capital | Washington | |||||
Non-Profit Foundation | Virginia |
First funding | 4/15/2021 | ||||
|---|---|---|---|---|---|
Last Funding | 4/28/2025 | ||||
Investor | |||||
Rounds | 2 Seed VC, Series A (2025) | ||||
Board Seats | |||||
Type | Venture Capital | Corporation | Venture Capital | Venture Capital | Non-Profit Foundation |
Location | Washington | Washington | Utah | Washington | Virginia |
Compare Gestalt Diagnostics to Competitors
Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.
Ellogon.AI provides a solution named EIDOS, which utilizes deep learning technology to assist medical experts in selecting suitable patients for immunotherapy by quantifying relevant biomarkers from histopathology images. The company operates within the healthcare sector, specifically targeting medical professionals involved in cancer treatment and research. It was founded in 2019 and is based in Amsterdam, Netherlands.
Alpenglow Biosciences focuses on drug development and clinical diagnostics using 3D imaging technology in the life sciences sector. The company provides sample preparation, open-top light-sheet microscopy, cloud-based processing and storage, 3D visualization, and AI analysis. Alpenglow's technology aims to enhance understanding of biological systems for pharmaceutical research. Alpenglow Biosciences was formerly known as Lightspeed Microscopy. It was founded in 2018 and is based in Seattle, Washington.
Nucleai focuses on spatial biology in precision medicine. The company provides artificial intelligence (AI)-powered image analysis applications to pharmaceutical companies and clinicians, enhancing drug development and supporting treatment decisions. It primarily serves the pharmaceutical industry. It was founded in 2018 and is based in Chicago, Illinois.
4D Path is a company that operates within the healthcare industry. They have developed a platform that measures and quantifies cell cycle deregulations and tumor microenvironment dynamics to predict patient responses to cancer therapies. Their technology provides biomarker profiling and stratification from histopathology images. It was founded in 2016 and is based in Newton Center, Massachusetts.
Mechanomind provides AI diagnostics for skin cancer within the healthcare technology sector. The company utilizes computer vision and deep learning to assist in the diagnosis of skin cancer, including the classification of skin tumor subtypes and offering decision support for pathologists. Mechanomind's technology is scanner and image quality agnostic, aimed at maintaining accuracy and efficiency in histopathology analysis. It was founded in 2015 and is based in New York, New York.
Loading...